Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRILLIANT: Beta-blocker Withdrawal in HFpEF with Chronotropic Incompetence
jRCT1031210030Recruiting
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of carvedilol in heart failure with preserved ejection fraction (HFpEF) (2 arms). Primary endpoint: Change in peak oxygen consumption. Started Jul 2021; status: recruiting.
02
Drugs
carvedilol
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on jRCT1031210030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031210030.